

## Custom synthesis offers strong visibility ahead...

**About the stock:** Commencing operations in 1991, Neogen Chemicals manufactures specialty organic bromine-based chemical compounds as well as specialty inorganic lithium-based chemicals compounds.

- The company's products find application in pharmaceutical intermediates, agrochemical intermediates, engineering fluids, polymers additives and water treatment chemicals to name a few
- Neogen has two segments viz. (i) organic chemicals, (ii) inorganic chemicals of which organic chemical constitute ~80% of overall revenue while the rest comes from inorganic chemicals

**Q1FY22 Results:** Numbers were below estimates on account of spillover sales to the next quarter.

- Reported revenue growth of 11% YoY to ₹ 84.6 crore, led by higher growth from inorganic chemical segment (up 55% YoY)
- Gross margins rose 690 bps YoY to ~45% while EBITDA margin improved 80 bps YoY to 18.5%, due to higher other operating cost (up 50% YoY) and employee expenses (up 30% YoY)
- EBITDA was up 15% YoY to ₹ 15.6 crore
- PAT increased 20% YoY to ₹ 7.4 crore owing to lower taxes (28.1% vs. 30% in Q1FY21)

**What should investors do?** The stock appreciated at 65% CAGR in last two years.

- We retain **BUY** rating on the back of better growth outlook from custom synthesis business

**Target Price and Valuation:** We value Neogen Chemicals at 38x P/E FY23E EPS to arrive at a revised target price of ₹ 1095/share (earlier ₹ 1085/share).

### Key triggers for future price performance:

- Phase 1 and Phase 2 capex at Dahej bodes well for advance intermediates and custom synthesis revenue growth
- Higher share of value added business portfolio to improve margins profile of the business
- Allocation of incremental FCF towards organic/inorganic growth likely to expand return ratios further

**Alternate Stock Idea:** Apart from Neogen Chemicals, in our chemical coverage we also like Sumitomo Chemicals.

- Trigger for Sumitomo Chemical's future revenue growth would be increasing CRAMS opportunity from SCC Japan and Nufarm
- BUY with a target price of ₹ 505

### Key Financial Summary

(₹ Crore)	FY19	FY20	FY21	5 year CAGR (FY16-21)	FY22E	FY23E	2 year CAGR (FY21-23E)
Net Revenue	239.1	306.1	336.4	25.3%	446.3	585.9	32.0%
EBITDA	43.4	58.1	64.4	35.5%	87.0	120.1	36.6%
EBITDA Margins (%)	18.2%	19.0%	19.1%		19.5%	20.5%	
Adj. PAT	21.0	28.6	31.3	43.3%	43.9	67.2	46.4%
Adj. EPS (₹)	10.4	12.3	13.4		18.8	28.8	
EV/EBITDA	44.1x	38.3x	35.6x		26.7x	19.4x	
P/E	86.0x	73.1x	66.8x		47.7x	31.2x	
ROE (%)	29.8	18.3	17.1		19.8	23.7	
ROCE (%)	22.2	18.4	15.1		16.5	20.1	

Source: Company, ICICI Direct Research




### Particulars

Particular	Amount
Market cap (₹ Crore)	2,093
FY21 Total Debt (₹ Crore)	202
FY21 Cash & Inv (₹ Crore)	1
EV (₹ Crore)	2,294
52 Week H/L	1028/590
Equity Capital (₹ Crore)	23.3
Face Value (₹)	10

### Shareholding pattern

in %	Sept-20	Dec-20	Mar-21	Jun-21
Promoter	64.3	64.3	64.3	64.3
DIL	16.2	15.5	14.8	14.1
FII	4.8	4.8	4.8	4.7
Others	14.7	15.4	16.1	16.9

### Price Chart



### Recent event & key risks

- Trial batches from phase 1 project at Dahej started
- Key Risk:** (i) Lower lithium prices to impact inorganic chemical performance ii) Slowdown in the end user industry and thereby stretched WC to impact balance sheet

### Research Analyst

Mitesh Shah  
mitesh.sha@icicisecurities.com

Dhavan Shah  
dhavan.shah@icicisecurities.com

Siddhant Khandekar  
siddhant.khandekar@icicisecurities.com

## Key takeaways of recent quarter & conference call highlight

### Q1FY22 Results: Better performance from inorganic chemical leads overall growth


- **Organic Chemical:** Revenues were up 3% YoY to ₹ 68 crore. There was higher COGS for this quarter (76.2% of revenue vs. 56.8% in Q1FY21), while there have been changes in inventory of around ₹ 18 crore. We believe part of this is spillover sales owing to some challenges (primarily logistic related). The company had already started batch production from its phase 1 capacity at Dahej. Two contracts for custom synthesis at the initial stage are expected to contribute around ₹ 60-80 crore for this fiscal year. Thus, we believe entire part would be distributed in the remaining three quarters
- **Inorganic Chemical:** The company had set up 1200 MT of capacity at Dahej last year. Thus, better utilisation of new capacity led higher volume growth. This, in turn, supported strong revenue growth during the quarter. Revenue was up 55% YoY to ₹ 17 crore

### Q1FY22 Earnings Conference Call highlights

- The company has been witnessing favourable demand trends across its key segments
- Mahape and Baroda units are operating at more than 80% utilisation
- **Custom Synthesis** – The company supplies to around 10 odd customers under its portfolio. It is engaging with eight to 10 new customers for several projects. The endeavour remains to add new customers under this portfolio going ahead
- Advance intermediates currently comprise ~25-30% of overall revenue. It is expected to inch up to 40% once Dahej capacity gets commissioned
- **Phase 1 Dahej Capex** – Trial production has commenced. They have received product approval from several customers. They will start dispatching from Q2FY22
- **Phase 2 capex:** Around 75% of reactors would be installed by the end of Q2FY22, Q3FY22
- Due to product mix changes, gross margins trend would be expected at 40-44% against earlier guided 38-42%
- Two new customers would contribute revenues to the tune of ₹ 60-80 crore this year
- The revenue guidance for the year remained unchanged at ₹ 450 crore


## Financial story in charts....

## Exhibit 1: Revenue trend (₹ crore)




Source: Company, ICICI Direct Research

## Exhibit 2: EBITDA (₹ crore) and OPM (%) trend



Source: Company, ICICI Direct Research

## Exhibit 3: PAT growth trend (₹ crore)



Source: Company, ICICI Direct Research

## Financial summary

Exhibit 4: Profit and loss statement					
Year end March	FY19	FY20	FY21	FY22E	₹ crore
<b>Total Operating Income</b>	<b>239.1</b>	<b>306.1</b>	<b>336.4</b>	<b>446.3</b>	<b>585.9</b>
Growth (%)	48.3	28.1	9.9	32.7	31.3
Raw Material Expenses	140.7	184.1	197.6	258.9	336.9
<b>Gross Profit</b>	<b>98.4</b>	<b>122.0</b>	<b>138.8</b>	<b>187.5</b>	<b>249.0</b>
Employee Cost	11.2	17.3	20.1	26.8	35.2
Other Operating Expenses	43.8	46.7	54.4	73.6	93.7
<b>EBITDA</b>	<b>43.4</b>	<b>58.1</b>	<b>64.4</b>	<b>87.0</b>	<b>120.1</b>
Growth (%)	49.8	33.7	10.9	35.2	38.0
Other Income	0.6	0.2	0.5	0.7	0.8
<b>EBITDA, including OI</b>	<b>44.0</b>	<b>58.3</b>	<b>64.9</b>	<b>87.7</b>	<b>120.9</b>
Depreciation	2.8	5.2	6.9	9.7	12.2
Net Interest Exp.	11.9	11.9	13.8	17.0	19.1
Other exceptional items	0.0	0.0	0.0	0.0	0.0
<b>PBT</b>	<b>29.3</b>	<b>41.1</b>	<b>44.2</b>	<b>61.0</b>	<b>89.6</b>
Total Tax	8.3	12.5	12.9	17.1	22.4
Tax Rate	28.4%	30.3%	29.1%	28.0%	25.0%
<b>PAT</b>	<b>21.0</b>	<b>28.6</b>	<b>31.3</b>	<b>43.9</b>	<b>67.2</b>
Adj.PAT after Minority interest	21.0	28.6	31.3	43.9	67.2
Adj. EPS (₹)	10.4	12.3	13.4	18.8	28.8
Shares Outstanding	2.0	2.3	2.3	2.3	2.3

Source: Company, ICICI Direct Research

Exhibit 5: Cash flow statement					
Year end March	FY19	FY20	FY21	FY22E	₹ crore
PBT & Extraordinary	29.3	41.1	44.2	61.0	89.6
Depreciation	2.8	5.2	6.9	9.7	12.2
After other adjustments					
(Inc) / Dec in Working Capital	-42.4	-85.1	36.6	-64.1	-66.9
Taxes	-5.5	-12.7	-10.4	-17.1	-22.4
Others	12.1	16.9	6.2	17.0	19.1
<b>CF from operating activities</b>	<b>-3.7</b>	<b>-34.5</b>	<b>83.6</b>	<b>6.5</b>	<b>31.6</b>
Purchase of Fixed Assets	-18.4	-26.5	-135.0	-17.3	-15.0
Others	-1.7	-2.1	0.4	0.0	0.0
<b>CF from investing activities</b>	<b>-20.1</b>	<b>-28.6</b>	<b>-134.6</b>	<b>-17.3</b>	<b>-15.0</b>
Proceeds from issue of shares	0.0	70.0	0.0	0.0	0.0
Borrowings (Net)	38.2	16.5	69.6	50.0	5.0
Others	-14.3	-23.9	-18.9	-22.3	-24.3
<b>CF from financing activities</b>	<b>24.0</b>	<b>62.6</b>	<b>50.7</b>	<b>27.7</b>	<b>-19.3</b>
Net cash flow	0.2	-0.5	-0.3	16.8	-2.7
Effects of foreign currency translation	0.0	0.0	0.0	0.0	0.0
Opening Cash	1.8	2.0	1.5	1.2	18.1
<b>Closing Cash</b>	<b>2.0</b>	<b>1.5</b>	<b>1.2</b>	<b>18.1</b>	<b>15.3</b>

Source: Company, ICICI Direct Research

Exhibit 6: Balance sheet					
Year end March	FY19	FY20	FY21	FY22E	₹ crore
<b>Liabilities</b>					
Share Capital	20.1	23.3	23.3	23.3	23.3
Reserves	50.1	132.9	159.7	198.3	260.3
<b>Total Shareholders Funds</b>	<b>70.2</b>	<b>156.2</b>	<b>183.0</b>	<b>221.7</b>	<b>283.6</b>
Minority Interest	0.0	0.0	0.0	0.0	0.0
Long Term Borrowings	50.6	30.4	116.1	156.1	166.1
Net Deferred Tax liability	4.9	5.6	8.2	8.2	8.2
Other long term liabilities	2.0	9.2	7.7	8.0	10.5
Long term provisions	2.0	3.6	3.0	4.3	5.7
<b>Current Liabilities and Provisions</b>					
Short term borrowings	65.2	101.9	85.8	95.8	90.8
Trade Payables	42.8	35.9	66.1	85.6	112.4
Other Current Liabilities	7.7	10.6	20.9	27.8	36.4
Short Term Provisions	1.1	1.5	1.1	1.5	1.9
Total Current Liabilities	116.8	149.9	173.9	210.6	241.5
<b>Total Liabilities</b>	<b>246.4</b>	<b>354.9</b>	<b>492.0</b>	<b>608.9</b>	<b>715.6</b>
<b>Assets</b>					
Net Block	82.8	110.6	126.7	204.0	251.8
Capital Work in Progress	0.4	2.7	114.7	45.0	0.0
Intangible assets under devl.	0.0	0.0	0.0	0.0	0.0
Goodwill on Consolidation	0.0	0.0	0.0	0.0	0.0
Non-current investments	0.5	0.6	0.8	0.8	0.8
Deferred tax assets	0.0	0.0	0.0	0.0	0.0
Long term loans and advances	2.5	5.9	7.3	7.9	10.3
Other Non Current Assets	0.4	4.1	2.3	8.8	11.5
<b>Current Assets, Loans &amp; Advances</b>					
Current Investments	0.0	0.0	0.0	0.0	0.0
Inventories	72.4	129.9	114.0	165.1	216.7
Sundry Debtors	60.7	75.2	78.6	97.8	128.4
Cash and Bank	2.0	1.5	1.2	18.1	15.3
Loans and Advances	0.0	0.0	0.0	0.0	0.0
Other Current assets	24.7	24.5	46.4	61.5	80.8
Current Assets	159.8	231.1	240.2	342.5	441.2
<b>Total Assets</b>	<b>246.5</b>	<b>354.9</b>	<b>492.0</b>	<b>608.9</b>	<b>715.6</b>

Source: Company, ICICI Direct Research

Exhibit 7: Key ratios					
Year end March	FY19	FY20	FY21	FY22E	FY23E
<u>Per share data (₹)</u>					
Adj. EPS	10.4	12.3	13.4	18.8	28.8
Adj. Cash EPS	11.8	14.5	16.4	23.0	34.0
BV	35.0	67.0	78.4	95.0	121.5
DPS	0.0	1.5	2.3	2.3	2.3
<u>Operating Ratios (%)</u>					
Gross Margin (%)	41.1	39.9	41.3	42.0	42.5
EBITDA Margin (%)	18.2	19.0	19.1	19.5	20.5
PAT Margin (%)	8.8	9.4	9.3	9.8	11.5
Debtor Days	93	90	85	80	80
Inventory Days	111	155	124	135	135
Creditor Days	65	43	72	70	70
Cash Conversion Cycle	138	202	137	145	145
<u>Return Ratios (%)</u>					
Return on Assets (%)	8.5	8.1	6.4	7.2	9.4
RoCE (%)	22.2	18.4	15.1	16.5	20.1
Core RoIC (%)	22.1	18.4	15.0	17.0	20.5
RoE (%)	29.8	18.3	17.1	19.8	23.7
<u>Solvency Ratios</u>					
Total Debt / Equity	1.6	0.8	1.1	1.1	0.9
Interest Coverage	3.5	4.4	4.2	4.6	5.7
Current Ratio	1.4	1.5	1.4	1.6	1.8
Quick Ratio	0.7	0.7	0.7	0.8	0.9
<u>Valuation Ratios (x)</u>					
EV/EBITDA	44.1	38.3	35.6	26.7	19.4
P/E	86.0	73.1	66.8	47.7	31.2
P/B	25.7	13.4	11.4	9.4	7.4
EV/Sales	8.0	7.3	6.8	5.2	4.0

Source: Company, ICICI Direct Research

## Exhibit 8: ICICI Direct coverage universe (Chemicals)

Company	CMP		M Cap		EPS (₹)			P/E (x)		EV/EBITDA (x)			RoCE (%)		RoE (%)	
	(₹)	TP(₹)	Rating	(₹ Cr)	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E	FY21	FY22E	FY23E
PI Industries	3316	3,855	Buy	50,403	48.6	59.2	77.1	68.3	56.0	43.0	47.8	39.2	30.1	17.2	18.6	20.4
Aarti Industries	853	960	Buy	30,927	30.2	72.8	60.0	55.2	22.9	27.8	32.2	23.5	18.0	10.7	12.7	15.3
Sumitomo Chemical	431	505	Buy	21,513	6.9	8.5	10.1	62.3	50.6	42.6	43.1	35.1	29.0	29.8	29.3	28.1
Vinati Organics	1954	2,300	Buy	20,086	26.2	40.2	44.3	74.6	48.6	44.1	56.4	36.2	32.3	21.7	29.4	27.1
Tata Chemical	824	925	Hold	20,997	10.1	39.1	42.6	81.9	21.1	19.3	15.8	10.0	8.3	4.1	7.1	7.7
Navin Fluorine	3720	3,712	Hold	18,413	45.0	53.0	73.1	82.6	70.2	50.9	57.5	49.7	33.9	21.0	19.0	22.6
Rallis India	320	400	Buy	6,215	11.4	12.7	16.0	28.1	25.1	20.0	18.4	16.8	13.0	18.0	17.7	20.0
Sudarshan chemical	752	775	Buy	5,204	20.4	24.4	29.9	36.9	30.8	25.1	19.9	16.5	14.2	15.2	16.3	17.9
Neogen Chemicals	897	1,095	Buy	2,093	13.4	18.8	28.8	66.8	47.7	31.2	35.6	26.7	19.4	15.1	16.5	20.1

Source: Bloomberg, ICICI Direct Research

## RATING RATIONALE

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

[pankaj.pandey@icicisecurities.com](mailto:pankaj.pandey@icicisecurities.com)

ICICI Direct Research Desk,  
ICICI Securities Limited,  
1st Floor, Akruti Trade Centre,  
Road No 7, MIDC,  
Andheri (East)  
Mumbai – 400 093  
[research@icicidirect.com](mailto:research@icicidirect.com)

## ANALYST CERTIFICATION

I/We, Mitesh Shah, (cleared all 3 levels of CFA), Dhavan Shah, MS (Finance), Siddhant Khandekar, Inter CA Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on [www.icicibank.com](http://www.icicibank.com).

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit [icicidirect.com](http://icicidirect.com) to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.